The goals of treatment are amelioration of symptoms and prevention of complications. Mild alcohol withdrawal can be managed with a quiet, supportive environment, reorientation, and one-to-one contact. If patients progress symptomatically despite a supportive environment, pharmacologic treatment should be instituted. As previously noted, the symptoms of withdrawal are primarily the manifestations of autonomic hyperactivity, and the cornerstone of treatment is benzodiazepines.
All benzodiazepines are effective. They can be used safely to replace the alcohol-depressant effects on the CNS, and their use can be rapidly tapered as symptoms abate. Multiple randomized controlled trials have shown the superiority of benzodiazepines to placebo in the treatment of alcohol withdrawal.
Using the shorter-acting formulations may be advantageous, especially in elderly persons and in patients with hepatic dysfunction. In otherwise healthy patients, the longer-acting formulations are acceptable. Familiarity with the intravenous dose administered to a critically ill patient or to a patient in whom oral intake has been restricted is important. Intramuscular absorption is unpredictable and probably should be avoided. The preferred modes of administration are oral and intravenous ().
A key point in treating alcohol withdrawal is to begin with a larger dose of benzodiazepines than is commonly used when these drugs are prescribed for anxiety. This approach is necessary to overcome the patient’s autonomic hyperactivity. The patient’s response should then be observed, and the dosage adjusted accordingly. Many treatment centers have used fixed-dose schedules for withdrawal. Recent studies, however, have promoted a “symptomtriggered approach”
that involves repeated assessments of the patient. This important advance in the treatment of alcohol withdrawal results in less total drug use and seems to be as efficacious as the fixed-dose schedules. The following illustrative case describes the symptom-triggered treatment approach.
ILLUSTRATIVE CASE
A 48-year-old man is hospitalized because of pneumonia. He admits to drinking one or two martinis a day. On the second hospital day, an increased heart rate, some tremulousness and restlessness, and increased blood pressure are noted. On physical examination, the patient is alert, somewhat agitated, tremulous, and oriented to person only, findings that definitely differ from those on examination at admission. No history of liver disease or previous alcohol withdrawal is evident. His respiratory status seems stable, and a repeated examination reveals no new signs of trauma or changes from the admission assessment other than disorientation and restlessness. Results of blood gas studies, glucose testing, electrocardiography, and electrolytes are stable. On the basis of the CIW A-Ar, the patient has a score of 40, an indication of a definite need for pharmacologic treatment. He is given an oral dose of diazepam (20 mg) and reexamined in 1 l/2 to 2 hours, at which time his score is 32. He is not overly sedated, and an additional dose of diazepam (20 mg) is administered; he is reassessed in about 2 hours. Again, he is not sedated, although he is somewhat calmer; his score has decreased to 24. A third dose of diazepam (10 mg) is given, and he is reexamined in 2 to 4 hours; his score is 19. He is given 5 mg of diazepam and is reassessed in about 4 hours.
ALTERNATIVES TO BENZODIAZEPINE TREATMENT
Several alternatives to benzodiazepines are available that can be used adjunctively and, occasionally, independently. β-Adrenergic blockers are useful for controlling blood pressure and tachyarrhythmias. Most of the arrhythmias that patients experience are responsive to β-blockade; however, the usual contraindications, including bronchospasm, heart block, and congestive heart failure, must be considered. Atenolol has been used widely and is helpful for single-day dosing; associated CNS side effects are minimal.
The β blockers, however, do not prevent progression to more serious symptoms of withdrawal and should not be used alone but should be used in conjunction with benzodiazepines. Moreover, they may mask symptoms of alcohol withdrawal.
α-Blockers have been used to treat the hypertension associated with alcohol withdrawal. Clonidine hydrochloride, which has been studied extensively, is available in a patch preparation that is helpful for patients in whom oral intake has been restricted. As with β-blockers, the α-blockers should not be used alone but should be used in conjunction with benzodiazepines.
They also can mask symptoms of alcohol withdrawal. Thus, some experts warn against the use of both &aa- and f3-blockers.
Phenobarbital has the advantage of being long acting (half-life is 96 to 99 hours, similar to that of diazepam metabolites). Occasionally, only one or two doses are necessary, and the seizure threshold is increased in patients experiencing alcohol withdrawal. This drug has been used widely in Europe but infrequently in the United States, inasmuch as American physicians seem more comfortable and familiar with the benzodiazepines. Carbamazepine and valproic acid have also been used in Europe to treat alcohol withdrawal and are effective; however, North American experience with these agents is minimal. Similar to phenobarbital, they increase the seizure threshold. All three of these drugs (phenobarbital, carbamazepine, and valproic acid) can be used alone rather than in conjunction with benzodiazepines.
Magnesium can be used to increase the seizure threshold if the magnesium level is low. If, however, the initial magnesium level is normal, magnesium supplementation has probably little associated benefit. In addition, renal function must be normal before magnesium supplementation can be considered.
Use of thiamine should always be considered. As subsequently discussed, administration of thiamine is the main method for preventing Wernicke’s encephalopathy and Korsakoff’s psychosis. It is safe and easy to administer (intramuscularly, intravenously, and orally) at 100 mg/day during the first few days of withdrawal. The only caveat is that, if a patient has a thiamine deficiency, administration of high-concentration glucose solutions without thiamine can precipitate acute Wernicke’s encephalopathy. In patients with oculogyric crises, high doses (up to 1,000 mg/day) have been used.
Multivitamins are useful if the patient is clinically malnourished. If, however, the patient seems to have a relatively normal state of nourishment on examination and routine laboratory tests (albumin and total protein), multivitamins have probably little associated benefit.
COMPLICATIONS
Seizures.—-Alcohol withdrawal-related seizures have been reported to occur in up to
33% of patients who have consumed alcohol 48 to 87 days before hospitalization.
Sei zures generally occur during the first 48 hours and before delirium develops.
,
They are usually generalized, selflimited, and single or occur in a short series. Intravenous administration of diazepam can be used to stop an acute episode. The use of phenytoin and the need for a loading dose of long-term anticonvulsant therapy are two issues that frequently arise. In general, the physician should consider anticonvulsant therapy if the patient has (1) a history of alcohol withdrawal-related seizures, (2) recurrent seizures after admission, or (3) a history of a prior seizure disorder unrelated to intake of alcohol.
Because of the varied histories in patients, both an anatomic and a metabolic assessment are important in determining the cause of the seizure. Imaging of the head and neurologic consultation should be strongly considered, particularly if the seizure occurs after delirium has begun or if the patient has multiple seizures. In addition, in a febrile patient who is having a seizure, a lumbar puncture is almost always necessary.
Delirium Tremens.—-The later, more serious phases of alcohol withdrawal are characterized by clouding of the sensorium, profound autonomic hyperactivity, and hallucinations. Haloperidol and phenothiazines can be used to help control hallucinations. These drugs, however, can lower the seizure threshold and should be used cautiously, either alone or with benzodiazepines. Although the dose should be individualized, initiation of a low dose is prudent, especially if the patient has already received benzodiazepines, and subsequent doses can be increased as necessary.
Arrhythmias.—-As previously noted, most cardiac arrhythmias associated with alcohol withdrawal are tachyarrhythmias. Although such arrhythmias respond well to β-blockers, the treatment regimen should be as that for any patient with arrhythmias.
Wernicke-Korsakoff Syndrome.—– The Wernicke- Wernicke Korsakoff syndrome is manifested by ataxia, cognitive impairment, and oculogyric crises attributed to thiamine deficiency. Korsakoff’s psychosis, a confabulatory psychosis, is believed to be related to a thiamine deficiency that may or may not follow typical Wernicke’s encephalopathy. Accordingly, thiamine should be considered for all patients who are undergoing treatment of alcohol withdrawal to prevent these complications. Chronic and recurring episodes of Wernicke’s encephalopathy can lead to chronic and irreversible dementia.
Psychiatric.—-Some patients experiencing alcohol withdrawal have underlying psychiatric diagnoses, especially depression.
After the acute treatment period has been completed, both chemical dependence counseling and psychiatric assessment can be initiated. Patients admitted to medical and surgical wards who have not heretofore recognized their difficulties with alcohol may be willing to discuss long-term treatment options. The opportunity for counseling should not be overlooked, and the skills of the chemical dependence counselor should be used.
General.—-Dehydration, fluid and electrolyte disturbances, infection, pancreatitis, and alcoholic ketoacidosis are commonplace in patients experiencing alcohol withdrawal; a thorough initial examination and treatment are necessary. Management of these conditions is similar to that in other patients and thus will not be specifically addressed.
CONCLUSION
In patients experiencing alcohol withdrawal during hospitalization, the physician must perform a thorough physical examination. Occult infection, trauma, or the possibility of withdrawal from multiple drugs must be considered. Criteria from the DSM-IV can be used to help with the diagnosis.
Benzodiazepines are the drugs of choice. After administration of a trial load, the patient’s response should be noted. A symptom-triggered approach is recommended. The drug should be rapidly tapered as symptoms abate. Fixed-dose schedules should be avoided. The CIWA-Ar should be used to help adjust dosage, detect complications, and identify patients who require more intensive therapy. α- or β- Blockers should be considered for autonomic hyperactivity that is not controlled with the benzodiazepines; however, such intervention cannot be used alone. Haloperidol can be used for hallucinations; however, administer cautiously if used alone. Complications, including seizures, arrhythmias, and infection, can be treated as usual. The skills and expertise of the available chemical dependence services should be used.